American Diabetes Association 60th Scientific Sessions, 2000

Bloomgarden, Zachary T.

doi:10.2337/diacare.24.5.946

Cited by 34 publications

(14 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This pathogenesis involves hematological alterations (Jones & Peterson, ) and hyperglycemia‐induced structural and functional modifications (Jeffcoate, Price, Harding, & International Working Group, ) in cells and connective tissue. Compromised wound healing remains a costly and complex clinical issue in this population (Bloomgarden, ).…”

Section: Discussionmentioning

confidence: 99%

Diabetes is not associated with increased rates of free flap failure: Analysis of outcomes in 6030 patients from the ACS‐NSQIP database

et al. 2018

View full text Add to dashboard Cite

Our study evaluated the largest national cohort of free flap procedures. These results suggest that diabetes is not associated with increased rates of flap failure. However, diabetic patients are at significantly higher risk of postoperative deep incisional SSI, wound dehiscence, and longer LOS. Our findings provide the most concrete evidence to date in support of free flap reconstruction in diabetic patients, but highlight the need for heightened clinical vigilance and wound care for optimal outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Diabetes is not associated with increased rates of free flap failure: Analysis of outcomes in 6030 patients from the ACS‐NSQIP database

et al. 2018

View full text Add to dashboard Cite

show abstract

“…4,5 Despite efforts to decrease the number of amputations in the United States, their number grew from 54,000, in 1990 6 to 92,000, in 1999. 7 The annual cost of diabetic neuropathy and its complications ranges between US$ 4.6 and US$ 13.7 billion in the United States. 8 In spite of the shortage of global studies on diabetes, it is estimated that there will be an increase from 171 million diabetics in 2000 to 366 million in 2030.…”

Section: Introductionmentioning

confidence: 99%

Estudo da anatomia do nervo tibial e seus ramos ao nível do terço distal da perna

Torres

Ferreira²

2012

Acta ortop. bras.

View full text Add to dashboard Cite

ObjectiveDetermine, through dissection in fresh cadavers, the topographic anatomy of the tibial nerve and its branches at the ankle, in relation to the tarsal tunnel.MethodsBilateral dissections were performed on 26 fresh cadavers and the locations of the tibial nerve bifurcation and its branches were measured in millimeters. For the calcaneal branches, the amount and their respective nerves of origin were also analyzed.ResultsThe tibial nerve bifurcation occurred under the tunnel in 88% of the cases and proximally in 12%. As for the calcaneal branches, the medial presented with one (58%), two (34%) and three (8%) branches, with the most common source occurring in the tibial nerve (90%) and the lower with a single branch per leg and lateral plantar nerve as the most common origin (70%). Level of Evidence, V Expert opinion.

show abstract

“…Among patient groups commonly developing lower extremity ulcers, the presence of diabetes mellitus is a major predictor of limb loss [1]. In the USA, over 80,000 major amputations are performed each year in patients with diabetes [2]. The number of amputations has increased by nearly 70% in the last 10 years, and the rate of amputation per person has increased nearly 40% [101].…”

mentioning

confidence: 99%

Dermagraft®, a bioengineered human dermal equivalent for the treatment of chronic nonhealing diabetic foot ulcer

Marston¹

2004

Expert Review of Medical Devices

107

View full text Add to dashboard Cite

Chronic nonhealing diabetic foot ulcers are a common medical problem that may precede severe complications such as infection, sepsis and limb loss. Current standard methods of treatment are aimed at removing necrotic debris, controlling infection, and relieving chronic pressure on the wound. Unfortunately, healing rates are poor with standard treatment, averaging 12-20 weeks in clinical trials. A new strategy for the treatment of diabetic foot ulcers has been developed through tissue engineering, allowing the application of healthy living skin cells to assist in the healing process. It is hoped that the living tissue will release appropriate quantities of growth factors, cytokines and other proteins to stimulate the chronic wound bed and accelerate healing. Dermagraft (Smith & Nephew) is a neonatal-derived bioengineered tissue comprised of dermal fibroblasts. In this article, the structure and behavior of this tissue will be examined, focusing particularly on the randomized clinical trials performed to justify its use in diabetic foot ulcers.

show abstract

American Diabetes Association 60th Scientific Sessions, 2000

Cited by 34 publications

References 12 publications

Diabetes is not associated with increased rates of free flap failure: Analysis of outcomes in 6030 patients from the ACS‐NSQIP database

Diabetes is not associated with increased rates of free flap failure: Analysis of outcomes in 6030 patients from the ACS‐NSQIP database

Estudo da anatomia do nervo tibial e seus ramos ao nível do terço distal da perna

Dermagraft®, a bioengineered human dermal equivalent for the treatment of chronic nonhealing diabetic foot ulcer

Contact Info

Product

Resources

About